Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Interest & Investment Income (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Interest & Investment Income for 7 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 2.64% to $10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.7 million through Dec 2025, down 10.92% year-over-year, with the annual reading at $43.7 million for FY2025, 10.92% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $10.6 million at Beam Therapeutics, down from $10.9 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $14.2 million in Q2 2024, with the low at -$52000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $7.7 million, with a median of $10.3 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income tumbled 120.8% in 2021, then skyrocketed 55255.56% in 2022.
  • Over 5 years, Interest & Investment Income stood at $54000.0 in 2021, then surged by 13994.44% to $7.6 million in 2022, then soared by 58.51% to $12.1 million in 2023, then dropped by 9.42% to $10.9 million in 2024, then dropped by 2.64% to $10.6 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $10.6 million, $10.9 million, and $12.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.